Business Context and Reporting Period
Company: Medical Transcription Billing, Corp. (Note: Metadata lists "Carecloud, Inc." but the filing text identifies the registrant as Medical Transcription Billing, Corp.)
Filing Type: Form 8-K (Current Report)
Date of Report: May 10, 2017
Reporting Period: Event date May 10, 2017; Closing expected May 15, 2017.
Context: The company, an emerging growth company, entered into a material definitive agreement for a registered direct offering of common stock and warrants to an institutional investor.
Key Financial Metrics
Transaction Details:
- Shares Sold: 1,000,000 shares of common stock.
- Share Price: $2.30 per share.
- Gross Proceeds: $2.3 million.
- Warrants Issued: 2,000,000 warrants to purchase common stock at an exercise price of $5.00 per share.
- Warrant Terms: Exercisable immediately; expire one year from issuance.
- Net Proceeds: Approximately $2.0 million (after deducting placement agent fees and estimated offering expenses).
- Use of Proceeds: General corporate purposes, including working capital.
Placement Agent Fees (Rodman & Renshaw):
- Cash Fee: 10% of the first $3 million of gross proceeds (approx. $230,000 for this transaction).
- Expenses: $60,000 non-accountable expenses plus up to $10,000 for reimbursable clearing expenses.
- Tail Fee: Applicable to offerings consummated within 18 months of termination regarding investors introduced by the agent.
Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the specific transaction proceeds.
Material Changes Versus Prior Period
This filing reports a discrete capital raising event rather than a comparative financial period. The material change is the entry into a Securities Purchase Agreement and the issuance of unregistered warrants, which alters the company's capital structure and cash position upon closing.
Guidance, Outlook, and Risks
Management Commentary: The company intends to use net proceeds for general corporate purposes and working capital. The transaction is subject to customary closing conditions.
Risks and Contingencies:
- Closing Conditions: The transaction is expected to close on or about May 15, 2017, subject to satisfaction of customary closing conditions.
- Dilution: The issuance of 1,000,000 shares and 2,000,000 warrants may result in dilution to existing shareholders.
- Unregistered Securities: Warrants and shares issuable upon exercise are sold without registration under the Securities Act of 1933, relying on Section 4(a)(2) and Rule 506 exemptions.
Important Facts for Investor Verification
- Verify the actual closing date of the offering (expected May 15, 2017) and confirmation of fund receipt.
- Confirm the exact net proceeds after final calculation of placement agent fees and expenses.
- Review the effective shelf registration statement (File No. 333-210391) and the accompanying prospectus supplement for the registered shares.
- Monitor the exercise of the 2,000,000 warrants issued at $5.00 per share over the one-year term.
- Check for any subsequent filings regarding the engagement letter with Rodman & Renshaw and potential tail fee obligations.